Science ❯ Biotechnology

Drug Discovery

Clinical Trials Clinical Research Artificial Intelligence AI Applications AI in Medicine AI in Healthcare Antibody-Drug Conjugates Recombinant Cells Small Molecule Drugs Protein Engineering Therapeutic Candidates Molecular Identification Cancer Research Therapeutics Bioengineering Clinical Studies Computational Modeling Virtual Cell Modeling Global Firms Kinase Inhibitors Laboratory Instruments Optogenetics Targeted Therapy Molecular Simulation Therapeutic Agents Proprietary Platforms Antibody Development Precision Therapies Small Molecule Therapies Regulatory Science Research Programs Molecular Licensing

Claude AI Designed Lab‑Confirmed Protein Binders for 14 of 15 Disease Targets

Lab builds confirmed about 27% of Claude's de novo designs bound, suggesting early drug discovery is now limited by compute and wet‑lab throughput.

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

Takeda Signs $600 Million‑Value AI Drug Discovery Deal With Insilico

Biogen to Buy RayThera for Up to $1 Billion

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

Google Launches Interactions API and Upgraded Gemini Deep Research for Developers

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

Integrated Biosciences’ Optogenetic Platform Advances Toward Aging and Pan-Antiviral Therapies